Insider Selling: Dynavax Technologies (NASDAQ:DVAX) COO Sells 30,000 Shares of Stock

Dynavax Technologies Corporation (NASDAQ:DVAX) COO David Novack sold 30,000 shares of the stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $15.49, for a total transaction of $464,700.00. Following the sale, the chief operating officer owned 111,451 shares in the company, valued at approximately $1,726,375.99. This trade represents a 21.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Dynavax Technologies Stock Performance

DVAX stock traded down $0.01 during mid-day trading on Monday, reaching $15.37. The company had a trading volume of 6,856,847 shares, compared to its average volume of 2,105,777. The stock has a market capitalization of $1.80 billion, a P/E ratio of -41.54 and a beta of 0.88. The stock’s 50-day simple moving average is $11.10 and its two-hundred day simple moving average is $10.58. Dynavax Technologies Corporation has a one year low of $9.20 and a one year high of $15.49. The company has a quick ratio of 6.94, a current ratio of 7.62 and a debt-to-equity ratio of 0.41.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The firm had revenue of $94.88 million during the quarter, compared to analysts’ expectations of $94.00 million. Research analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Profund Advisors LLC grew its holdings in shares of Dynavax Technologies by 2.7% during the 3rd quarter. Profund Advisors LLC now owns 38,380 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 995 shares in the last quarter. Parkman Healthcare Partners LLC increased its position in Dynavax Technologies by 0.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 271,306 shares of the biopharmaceutical company’s stock worth $2,694,000 after purchasing an additional 1,175 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,226 shares in the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of Dynavax Technologies by 0.9% during the 3rd quarter. Rafferty Asset Management LLC now owns 164,206 shares of the biopharmaceutical company’s stock valued at $1,631,000 after buying an additional 1,516 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in shares of Dynavax Technologies by 1.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 118,484 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 1,610 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Wall Street Zen raised shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Finally, William Blair cut shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.